Literature DB >> 33539485

Comparative performance of SARS-CoV-2 real-time PCR diagnostic assays on samples from Lagos, Nigeria.

Chika Kingsley Onwuamah1, Azuka Patrick Okwuraiwe1, Olumuyiwa B Salu2, Joseph O Shaibu1, Nnaemeka Ndodo3, Samuel O Amoo1, Leona C Okoli1, Fehintola A Ige1, Rahaman A Ahmed1, Munir Akinwale Bankole4, Judith O Sokei1, Bamidele Paul Mutiu4, James Ayorinde5, Babatunde Akeem Saka6, Celestina Obiekea3, Nwando Mba3, Richard A Adegbola1, Sunday Omilabu1,2, Chikwe Ihekweazu7, Babatunde Lawal Salako8, Rosemary Audu1.   

Abstract

A key element in containing the spread of the SARS-CoV-2 infection is quality diagnostics which is affected by several factors. We now report the comparative performance of five real-time diagnostic assays. Nasopharyngeal swab samples were obtained from persons seeking a diagnosis for SARS-CoV-2 infection in Lagos, Nigeria. The comparison was performed on the same negative, low, and high-positive sample set, with viral RNA extracted using the Qiagen Viral RNA Kit. All five assays are one-step reverse transcriptase real-time PCR assays. Testing was done according to each assay's manufacturer instructions for use using real-time PCR platforms. 63 samples were tested using the five qPCR assays, comprising of 15 negative samples, 15 positive samples (Ct = 16-30; one Ct = 35), and 33 samples with Tib MolBiol E-gene Ct value ranging from 36-41. All assays detected all high positive samples correctly. Three assays correctly identified all negative samples while two assays each failed to correctly identify one different negative sample. The consistent detection of positive samples at different Ct/Cq values gives an indication of when to repeat testing and/or establish more stringent in-house cut-off value. The varied performance of different diagnostic assays, mostly with emergency use approvals, for a novel virus is expected. Comparative assays' performance reported may guide laboratories to determine both their repeat testing Ct/Cq range and/or cut-off value.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33539485      PMCID: PMC7861429          DOI: 10.1371/journal.pone.0246637

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  4 in total

1.  Understanding SARS-CoV-2: Genetic Diversity, Transmission and Cure in Human.

Authors:  Abhay Bajaj; Hemant J Purohit
Journal:  Indian J Microbiol       Date:  2020-04-20       Impact factor: 2.461

2.  Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant.

Authors:  Maria Pachetti; Bruna Marini; Francesca Benedetti; Fabiola Giudici; Elisabetta Mauro; Paola Storici; Claudio Masciovecchio; Silvia Angeletti; Massimo Ciccozzi; Robert C Gallo; Davide Zella; Rudy Ippodrino
Journal:  J Transl Med       Date:  2020-04-22       Impact factor: 5.531

3.  Genomic variance of the 2019-nCoV coronavirus.

Authors:  Carmine Ceraolo; Federico M Giorgi
Journal:  J Med Virol       Date:  2020-02-19       Impact factor: 2.327

4.  The establishment of reference sequence for SARS-CoV-2 and variation analysis.

Authors:  Changtai Wang; Zhongping Liu; Zixiang Chen; Xin Huang; Mengyuan Xu; Tengfei He; Zhenhua Zhang
Journal:  J Med Virol       Date:  2020-03-20       Impact factor: 20.693

  4 in total
  4 in total

1.  High concordance in SARSCoV-2 detection between automated (Abbott m2000) and manual (DaAn gene) RT-PCR systems: The EDCTP PERFECT-Study in Cameroon.

Authors:  Nadine Nguendjoung Fainguem; Joseph Fokam; Ezechiel Ngoufack Jagni Semengue; Alex Durand Nka; Désiré Takou; Joshua Ageboh Nkembi-Leke; Claudia Alteri; Luna Colagrossi; Roméo Bouba Yagai; Collins Ambe Chenwi; Michel Carlos Tchouaket Tommo; Grace Angong Beloumou; Aude Christelle Ka'e; Sandrine Claire Ndjeyep Djupsa; Aissatou Abba; Laeticia Grace Heunko Yatchou; Krystel Nnomo Zam; Rachel Kamgaing; Samuel Martin Sosso; Lucien Mama; Nicaise Ndembi; Vittorio Colizzi; Carlo-Federico Perno; Giulia Cappelli; Alexis Ndjolo
Journal:  J Public Health Afr       Date:  2022-05-24

2.  Real-world SARS CoV-2 testing in Northern England during the first wave of the COVID-19 pandemic.

Authors:  Hamzah Z Farooq; Emma Davies; Benjamin Brown; Thomas Whitfield; Peter Tilston; Ashley McEwan; Andrew Birtles; Robert O'Hara; Hannah Spencer; Louise Hesketh; Shazaad Ahmad; Malcolm Guiver; Nicholas Machin
Journal:  J Infect       Date:  2021-04-21       Impact factor: 6.072

3.  Diagnostic performance of a colorimetric RT -LAMP for the identification of SARS-CoV-2: A multicenter prospective clinical evaluation in sub-Saharan Africa.

Authors:  Marycelin Mandu Baba; Molalegne Bitew; Joseph Fokam; Eric Agola Lelo; Ahmed Ahidjo; Kominist Asmamaw; Grace Angong Beloumou; Wallace Dimbuson Bulimo; Emanuele Buratti; Collins Chenwi; Hailu Dadi; Pierlanfranco D'Agaro; Laura De Conti; Nadine Fainguem; Galadima Gadzama; Paolo Maiuri; Janet Majanja; Wadegu Meshack; Alexis Ndjolo; Celine Nkenfou; Bamidele Soji Oderinde; Silvanos Mukunzi Opanda; Ludovica Segat; Cristiana Stuani; Samwel L Symekher; Desire Takou; Kassahun Tesfaye; Gianluca Triolo; Keyru Tuki; Serena Zacchigna; Alessandro Marcello
Journal:  EClinicalMedicine       Date:  2021-08-28

4.  Long Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study.

Authors:  Daliborka Bursac; Dimitris Petridis; Bojan Zaric; Tomi Kovacevic; Vladimir Stojsic; Tatjana Sarcev; Haidong Huang; Chong Bai; Wolfgang Hohenforst-Schmidt; Christoforos Kosmidis; Konstantinos Sapalidis; Konstantinos Romanidis; Nikolaos Courcoutsakis; Aimilios Lallas; Giorgos Tsakaldimis; Kyriakoula Chatzimichael; Chrysanthi Sardeli; Dimitris Matthaios; Paul Zarogoulidis; Chrysanthi Karapantzou
Journal:  Curr Health Sci J       Date:  2021-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.